Absci (NASDAQ:ABSI) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Absci (NASDAQ:ABSI) in a research note published on Wednesday morning,Benzinga reports. The brokerage currently has a $7.00 price objective on the stock.

Other equities analysts have also issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Absci in a research note on Wednesday, January 21st. HC Wainwright upped their target price on Absci from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Finally, Morgan Stanley cut Absci from an “overweight” rating to an “equal weight” rating and set a $4.32 price target for the company. in a research report on Thursday, January 8th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.08.

Absci Price Performance

NASDAQ:ABSI opened at $2.92 on Wednesday. The company’s fifty day moving average price is $2.77 and its 200-day moving average price is $3.21. Absci has a 1-year low of $2.01 and a 1-year high of $5.23. The firm has a market capitalization of $439.08 million, a P/E ratio of -3.44 and a beta of 2.12.

Absci (NASDAQ:ABSI) last posted its earnings results on Tuesday, March 24th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.07). Absci had a negative net margin of 4,113.68% and a negative return on equity of 61.95%. The business had revenue of $0.65 million for the quarter, compared to analyst estimates of $1.38 million. Equities analysts anticipate that Absci will post -0.89 EPS for the current fiscal year.

Insider Buying and Selling at Absci

In other news, insider Andreas Busch acquired 100,000 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was acquired at an average price of $2.29 per share, for a total transaction of $229,000.00. Following the completion of the transaction, the insider owned 421,446 shares in the company, valued at approximately $965,111.34. The trade was a 31.11% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sean Mcclain sold 26,761 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $2.99, for a total transaction of $80,015.39. Following the sale, the chief executive officer directly owned 8,334,567 shares in the company, valued at approximately $24,920,355.33. The trade was a 0.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 10.49% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Absci

Institutional investors and hedge funds have recently modified their holdings of the business. Quarry LP purchased a new position in Absci during the third quarter worth approximately $26,000. Scientech Research LLC acquired a new stake in Absci in the third quarter valued at approximately $31,000. HB Wealth Management LLC purchased a new stake in shares of Absci in the third quarter valued at approximately $31,000. Principal Financial Group Inc. acquired a new position in shares of Absci during the 3rd quarter worth approximately $31,000. Finally, Xponance LLC acquired a new position in shares of Absci during the 4th quarter worth approximately $37,000. Hedge funds and other institutional investors own 52.05% of the company’s stock.

Absci News Roundup

Here are the key news stories impacting Absci this week:

• Positive Sentiment: Early ABS-201 clinical progress — Absci reported dosing the first three SAD cohorts in the ABS-201 HEADLINE trial with favorable emerging safety data, a tangible pipeline milestone that supports longer-term value upside. Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
• Positive Sentiment: Analyst support — Needham & Company reaffirmed a Buy rating and set a $7.00 price target, implying substantial upside from current levels and providing a counterbalance to recent weak results. Needham buy rating reaffirmed (Benzinga)
• Neutral Sentiment: Full earnings call transcript and highlights are available — management framed Q4 and FY2025 results alongside strategic updates; investors should read the call for detail on cash runway, partnering plans, and program timelines. Absci Q4 2025 Earnings Call Transcript (Seeking Alpha)
• Neutral Sentiment: Pre-market coverage noted broader weakness — Absci appeared among names moving lower in pre-market commentary, reflecting market reaction to the combined earnings and pipeline headlines rather than a single clear driver. Absci, DigitalOcean and other big stocks moving lower in Wednesday’s pre-market session
• Neutral Sentiment: Short-interest data published in recent feeds looks unreliable/zeroed (reports show 0 shares and NaN changes); treat those numbers cautiously until exchanges/administrators reconcile them. (No reliable article link available.)
• Negative Sentiment: Quarterly miss — Absci reported Q4 EPS of ($0.23) versus consensus ($0.16) and revenue of $0.65M vs. $1.38M expected, a miss that reduces near-term fundamental support and likely fueled selling pressure. Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
• Negative Sentiment: Analyst downgrade citing pipeline pivot — A Seeking Alpha note downgraded Absci to Hold after management appears to de-emphasize ABS-101 in favor of ABS-201, a shift that could delay or reduce near-term value capture from earlier programs and compress the stock’s valuation. Absci: Downgrade To ‘Hold’ As ABS-101 On Back Burner And Pivot To ABS-201

Absci Company Profile

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.